CrownBio’s library of focussed FactSheets on
key Oncology and CVMD preclinical topics


The CrownBio library of focused FactSheets brings you highly specific information on a single topic, service, or subset of models to meet your Oncology and CardioVascular and Metabolic Disease (CVMD) research needs.

The FactSheet collection continues to grow and is regularly updated with our latest service and model updates. Bookmark this page and come back and see us soon. Don’t see what you need? Contact us today with your request.

CardioVascular and Metabolic Disease (CVMD)

CrownBio provides a range of FactSheets across our key disease areas, including:

Cardiovascular Disease  

  • Rodent models of cardiovascular disease technologies and resources including continuous telemetry blood pressure monitoring
  • The ZDSD polygenic rat model with functional leptin pathway, a highly translatable model which develops hypertension



Renal Disease    




CrownBio provides a comprehensive In Vivo Immunotherapy Translational Technology Platform, and our FactSheets bring you detailed information across a range of our immuno- oncology services:

CAR-T Cell Therapy Models

Humanized Models

Murine Efficacy/PD Models

  • Syngeneic models, showcasing our ever expanding syngeneic collection, FACS analysis, and checkpoint inhibitor benchmarking
  • MuScreen™ CrownBio’s large-scale, staggered screening platform to fast-track the in vivo screening of immunotherapy compounds
  • MuPrime™ - allografts of spontaneous murine tumors (from GEMM/carcinogen-induced models), studied in mice with complete immunocompetency
  • MuPrime mBR6004 which takes a closer look at our most highly studied MuPrime model including gene expression, immunohistochemistry, treatment data, and immune cell tumor infiltration analysis

Fusion Models 

Fusion oncogenic events are important targets for oncology research, potentially providing ‘druggable’ targets for subsets of cancer patients. We currently provide FactSheets on:

  • RET fusion in CRC PDX models, including model response to RET inhibitor treatment, and the development of acquired resistance models
  • FGFR3-TACC3 fusion in NSCLC and brain tumor PDX models, as well as bladder cancer Cell Line Derived Xenograft models. The FactSheet includes a wide range of treatment data and development of in vivo and in vitro resistance models

PDX Models 


In Vitro/Ex Vivo Assays